Use of liposomal amphotericin B in bone marrow transplant

Area of Science:

• Transplantation and Infectious Diseases
• Pharmacology and Toxicology

Background:

• Increased organ transplants worldwide correlate with a rise in fungal infections.
• Factors like neutropenia, immunosuppression, and graft-versus-host disease heighten susceptibility to fungal infections.
• Invasive fungal infections are challenging to diagnose, necessitating empirical antifungal therapy for febrile neutropenic patients.

Purpose of the Study:

• To evaluate the safety and efficacy of liposomal amphotericin B as a prophylactic antifungal agent in transplant recipients.
• To assess the cost-effectiveness and tolerability of liposomal amphotericin B compared to other antifungal strategies.

Main Methods:

• Review of clinical efficacy data, primarily from compassionate use studies and case series.
• Comparison of different liposomal amphotericin B formulations (Ambisome, Fungisome, and an Indian preparation).
• Analysis of treatment outcomes in over 150 transplant patients receiving an Indian liposomal amphotericin B preparation.

Main Results:

• Liposomal amphotericin B formulations offer reduced toxicity compared to conventional amphotericin B.
• An Indian liposomal amphotericin B preparation demonstrated safety and efficacy in over 150 transplant patients.
• Fungisome is effective at a dose of 1-3 mg/kg/day, while Ambisome requires 3 mg/kg/day.

Conclusions:

• Liposomal amphotericin B is a well-tolerated and effective option for managing fungal infections in transplant patients.
• Prophylactic use of liposomal amphotericin B is a cost-effective strategy with improved patient responses.
• The Indian liposomal amphotericin B preparation shows promise as a safe and effective treatment option.